The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. The reader should not assume that the information is accurate and complete. UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB APPROVAL Washington, D.C. 20549 OMB Number: 3235-0076 FORM D Estimated average burder hours per response: 4.00 Notice of Exempt Offering of Securities 1. Issuer's Identity Previous CIK (Filer ID Number) Entity Type None Names 0000882291 **BISHOP EQUITIES INC** X Corporation Name of Issuer Limited Partnership **AETHLON MEDICAL INC** Limited Liability Company Jurisdiction of Incorporation/Organization **General Partnership NEVADA** Year of Incorporation/Organization **Business Trust** Х Over Five Years Ago Other (Specify) Within Last Five Years (Specify Year) Yet to Be Formed 2. Principal Place of Business and Contact Information Name of Issuer **AETHLON MEDICAL INC** Street Address 1 Street Address 2 8910 UNIVERSITY CENTER LANE, SUITE 660 City State/Province/Country ZIP/PostalCode Phone Number of Issuer SAN DIEGO **CALIFORNIA** 92122 858-459-7800 3. Related Persons First Name Middle Name Last Name Joyce James Α. Street Address 1 Street Address 2 8910 UNIVERSITY CENTER LANE, SUITE 660 State/Province/Country ZIP/PostalCode City SAN DIEGO CALIFORNIA 92122 Relationship: X Executive Officer X Director Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name Tullis Richard H. Street Address 1 Street Address 2 8910 UNIVERSITY CENTER LANE, SUITE 660 City State/Province/Country ZIP/PostalCode SAN DIEGO **CALIFORNIA** 92122 Relationship: X Executive Officer X Director Promoter Clarification of Response (if Necessary): Last Name First Name Middle Name Barry, Jr. Franklyn S.

Street Address 2

Street Address 1

8910 UNIVERSITY CENTER LANE, SUITE 660		
City	State/Province/Country	ZIP/PostalCode
SAN DIEGO		92122
Relationship: Executive Officer X Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Broenniman	Edawrd	G.
Street Address 1	Street Address 2	
8910 UNIVERSITY CENTER LANE, SUITE 660		
City	State/Province/Country	ZIP/PostalCode
SAN DIEGO	CALIFORNIA	92122
Relationship: Executive Officer Director	Promoter	
Clarification of Response (if Necessary):		
Last Name	First Name	Middle Name
Kenley	Rodney	
Street Address 1	Street Address 2	
8910 UNIVERSITY CENTER LANE, SUITE		
660 City	State/Province/Country	ZIP/PostalCode
SAN DIEGO	CALIFORNIA	92122
Relationship: X Executive Officer Director	Promoter	
Clarification of Response (if Necessary):	2	
4. Industry Group		
	Health Care	
Agriculture	X Biotechnology	Retailing
Banking & Financial Services		Restaurants
Commercial Banking	Health Insurance	 Technology
	Hospitals & Physicians	Computers
	Pharmaceuticals	☐ ☐ Telecommunications
Investment Banking		
Pooled Investment Fund	Other Health Care	Other Technology
le lie leedel regiotored de	Manufacturing	Travel
an investment company under the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	Lodging & Conventions
Yes	Construction	Tourism & Travel Services
Other Banking & Financial Services	REITS & Finance	
Business Services	Residential	
Energy		Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Other Energy		

Revenue Range OR	Aggregate Net Asset Value Range				
X No Revenues	No Aggregate Net Asset Value				
\$1 - \$1,000,000	\$ 1 - \$5,000,000				
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000,000				
\$5,000,001 - \$25,000,000	\$ \$25,000,001 - \$50,000,000				
\$25,000,001 - \$100,000,000	\$50,000,001 - \$100,000,000				
Over \$100,000,000	Over \$100,000,000				
Decline to Disclose	Decline to Disclose				
Not Applicable	Not Applicable				
6. Federal Exemption(s) and Exclusion(s) Claimed (se	elect all that apply)				
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505				
	X Rule 506				
Rule 504 (b)(1)(i)	Securities Act Section 4(5)				
Rule 504 (b)(1)(ii)					
Rule 504 (b)(1)(iii)	Investment Company Act Section 3(c)				
	Section 3(c)(1) Section 3(c)(9)				
	Section 3(c)(2) Section 3(c)(10)				
	Section 3(c)(3) Section 3(c)(11)				
	Section 3(c)(4)				
	Section 3(c)(5)				
	Section 3(c)(6)				
	Section 3(c)(7)				
7. Type of Filing					
X New Notice Date of First Sale 2011-11-10	Sale Yet to Occur				
Amendment					
8. Duration of Offering					
Does the Issuer intend this offering to last more than one	e year? Yes No				
9. Type(s) of Securities Offered (select all that apply)					
Equity	Pooled Investment Fund Interests				
X Debt	Tenant-in-Common Securities				
X Option, Warrant or Other Right to Acquire Another Se	ecurity Mineral Property Securities				
Security to be Acquired Upon Exercise of Option, War Acquire Security	arrant or Other Right to				
10. Business Combination Transaction					
Is this offering being made in connection with a business or exchange offer?	s combination transaction, such as a merger, acquisition				
Clarification of Response (if Necessary):					
11. Minimum Investment					
Minimum investment accepted from any outside investor	r \$9,500 USD				
12. Sales Compensation					
Recipient	Recipient CRD Number None				

(Associated) Broker or Dealer None	(Associated) Broker or Dealer CRD Number	
Laidlaw & Company (UK) Ltd.	119037	
Street Address 1	Street Address 2	
90 Park Avenue		
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10016
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/non-US	
13. Offering and Sales Amounts		
Total Offering Amount \$1,000,000 USD or Indefinite		
Total Amount Sold \$210,000 USD		
Total Remaining to be Sold \$790,000 USD or Indefinite		
Clarification of Response (if Necessary):		
14. Investors		
Select if securities in the offering have been or may be sold to pers such non-accredited investors who already have invested in the off Regardless of whether securities in the offering have been or may total number of investors who already have invested in the offering	ering. be sold to persons who do not qualify as accredited investors	
15. Sales Commissions & Finder's Fees Expenses		
Provide separately the amounts of sales commissions and finders fees check the box next to the amount.	expenses, if any. If the amount of an expenditure is not know	n, provide an estimate and
Sales Commissions \$16,000 USD X Estimate		
Finders' Fees \$0 USD Estimate		
Clarification of Response (if Necessary):		
The \$16,000 cash payment to Laidlaw & Company represented an 8% acquire up to 323,492 shares of the Company's common stock.	sales commission. The Company also issued to Laidlaw as c	ompensation a warrant to
16. Use of Proceeds		
Provide the amount of the gross proceeds of the offering that has been executive officers, directors or promoters in response to Item 3 above.		
\$0 USD Estimate		
Clarification of Response (if Necessary):		
Signature and Submission		
Please verify the information you have entered and review the Ter notice.	ms of Submission below before signing and clicking SUE	BMIT below to file this
Terms of Submission		

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
AETHLON MEDICAL INC	/s/ James B. Frakes	James B. Frakes	Chief Financial Officer	2011-11-21

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.